FDA Puts “Accelerated Approval” Front And Center

Draft guidance calls for a clear statement in the Indications and Usage section of labeling that reflects a drug’s clearance under accelerated approval on the basis of a particular surrogate or clinical endpoint. The document also includes provisions for reflecting the withdrawal of accelerated approval in labeling.